Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Individualization in Children with Hematological Neoplasms
NCT03844360Phase 4Recruiting
- Start
- Jan 2016
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Modified Peptides, Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of bortezomib, eltrombopag, imatinib, dasatinib, pegaspargase in hematological neoplasms. Started Jan 2016; status: recruiting.
02
Drugs
03
Conditions
hematological neoplasms
Beyond the preview
Go deeper on NCT03844360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844360.